The COMP noted early clinical data indicate Zoci may demonstrate a more favourable effect than existing authorised therapies.

Lung cancer is the leading cause of cancer deaths among both men and women. Small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) are the two main types of lung cancer. Most lung ...

The accelerated approval for Jazz Pharmaceuticals’ small cell lung cancer (SCLC) drug Zepzelca may once again be in jeopardy.

The combination of tarlatamab and standard anti-PD-L1 therapy as first-line maintenance therapy led to “unprecedented” survival gains among patients with extensive-stage small cell lung cancer ...

Mona Bratter had trouble breathing after surgery in 2023 to treat her small-cell lung cancer (SCLC). But when her oncologist suggested palliative care to help manage her discomfort, she was hesitant. ...

Shares of Jazz Pharmaceuticals JAZZ fell more than 2% on Friday after the company announced disappointing results from a ...

Transcription factors, especially FOXP1, are crucial in SCLC chemoresistance, influencing drug sensitivity and resistance pathways. FOXP1 regulates SP8 expression via its super-enhancer, impacting the ...

The first patients in a phase 1/2 trial have received a combination of HPN328, an immunotherapy, and Tecentriq for small cell lung cancer. The first patients in a phase 1/2 trial with small cell lung ...

Small cell lung cancer (SCLC) often spreads to the brain, where it tends to be very aggressive. Although median survival is about 6 months, with advances in treatment, experts think life expectancy ...

Overall survival with serplulimab, a novel PD-1 inhibitor being developed in China for extensive-stage small cell lung cancer (ES-SCLC), appears better than that seen with two immune checkpoint ...

ATLANTA — One of two men at the center of an grand jury investigation into embezzlement within the Southern Christian Leadership Conference sat down with Channel 2 Action News for his first interview ...